Thomas Gruber

Dr. Thomas Gruber


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SASidar Aydin
Sidar Aydin
JPJavier Pareja
Javier Pareja
VSVivianne M. Schallenberg
Vivianne M. Schallenberg
AKArmelle Klopstein
Armelle Klopstein
TGThomas Gruber
Thomas Gruber
BEBritta Engelhardt
Britta Engelhardt
Blood-brain barrier (BBB) breakdown and immune cell infiltration into the central nervous system (CNS) are early hallmarks of multiple sclerosis (MS). High numbers of CD8+ T cells are found in MS lesions, and antigen (Ag) presentation at the BBB has been proposed to promote CD8+ T cell entry into the CNS. Here, we show that brain endothelial cells process and cross-present Ag, leading to effector CD8+ T cell differentiation. Under physiological flow in vitro, endothelial Ag presentation prevented CD8+ T cell crawling and diapedesis resulting in brain endothelial cell apoptosis and BBB breakdown. Brain endothelial Ag presentation in vivo was limited due to Ag uptake by CNS-resident macrophages but still reduced motility of Ag-specific CD8+ T cells within CNS microvessels. MHC class I-restricted Ag presentation at the BBB during neuroinflammation thus prohibits CD8+ T cell entry into the CNS and triggers CD8+ T cell-mediated focal BBB breakdown.

17 September 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
TGThomas Gruber
Thomas Gruber
MKMirela Kremenovic
Mirela Kremenovic
HSHassan Sadozai
Hassan Sadozai
NRNives Rombini
Nives Rombini
LBLukas Baeriswyl
Lukas Baeriswyl
MSMirjam Schenk
Mirjam Schenk
Myeloid cells orchestrate the antitumor immune response and influence the efficacy of immune checkpoint blockade (ICB) therapies. We and others have previously shown that IL-32 mediates DC differentiation and macrophage activation. Here, we demonstrate that IL-32 expression in human melanoma positively correlates with overall survival, response to ICB, and an immune-inflamed tumor microenvironment (TME) enriched in mature DC, M1 macrophages, and CD8 + T cells. Treatment of B16F10 murine melanomas with IL-32 increased the frequencies of activated, tumor-specific CD8 + T cells, leading to the induction of systemic tumor immunity. Our mechanistic in vivo studies revealed a potentially novel role of IL-32 in activating intratumoral DC and macrophages to act in concert to prime CD8 + T cells and recruit them into the TME through CCL5. Thereby, IL-32 treatment reduced tumor growth and rendered ICB-resistant B16F10 tumors responsive to anti–PD-1 therapy without toxicity. Furthermore, increased baseline IL-32 gene expression was associated with response to nivolumab and pembrolizumab in 2 independent cohorts of patients with melanoma, implying that IL-32 is a predictive biomarker for anti–PD-1 therapy. Collectively, this study suggests IL-32 as a potent adjuvant in immunotherapy to enhance the efficacy of ICB in patients with non–T cell–inflamed TME.

30 May 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
Thomas L. MooreThomas L. Moore
Thomas L. Moore
DHDaniel Hauser
Daniel Hauser
TGThomas Gruber
Thomas Gruber
BRBarbara Rothen-Rutishauser
Barbara Rothen-Rutishauser
MLMarco Lattuada
Marco Lattuada
RLRuth Lyck
Ruth Lyck

15 May 2018 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
PDF file
AGAna B García-Martín
Ana B García-Martín
PZPascale Zwicky
Pascale Zwicky
TGThomas Gruber
Thomas Gruber
CMChristoph Matti
Christoph Matti
FMFederica Moalli
Federica Moalli
RLRuth Lyck
Ruth Lyck
Melanoma is the most aggressive skin cancer in humans. One severe complication is the formation of brain metastasis, which requires extravasation of melanoma cells across the tight blood–brain barrier (BBB). Previously, VLA-4 has been assigned a role for the adhesive interaction of melanoma cells with non-BBB endothelial cells. However, the role of melanoma VLA-4 for breaching the BBB remained unknown. In this study, we used a mouse in vitro BBB model and imaged the shear resistant arrest of melanoma cells on the BBB. Similar to effector T cells, inflammatory conditions of the BBB increased the arrest of melanoma cells followed by a unique post-arrest behavior lacking immediate crawling. However, over time, melanoma cells intercalated into the BBB and compromised its barrier properties. Most importantly, antibody ablation of VLA-4 abrogated melanoma shear resistant arrest on and intercalation into the BBB and protected the BBB from barrier breakdown. A tissue microarray established from human brain metastasis revealed that indeed a majority of 92% of all human melanoma brain metastases stained VLA-4 positive. We propose VLA-4 as a target for the inhibition of brain metastasis formation in the context of personalized medicine identifying metastasizing VLA-4 positive melanoma.

16 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TGThomas Gruber
Thomas Gruber
SRSteve Robatel
Steve Robatel
MKMirela Kremenovic
Mirela Kremenovic
LBLukas Bäriswyl
Lukas Bäriswyl
Jürg GertschJürg Gertsch
Jürg Gertsch
MSMirjam Schenk
Mirjam Schenk
Agents targeting the endocannabinoid system (ECS) have gained attention as potential cancer treatments. Given recent evidence that cannabinoid receptor 2 (CB2R) regulates lymphocyte development and inflammation, we performed studies on CB2R in the immune response against melanoma. Analysis of The Cancer Genome Atlas (TCGA) data revealed a strong positive correlation between CB2R expression and survival, as well as B cell infiltration in human melanoma. In a murine melanoma model, CB2R expression reduced the growth of melanoma as well as the B cell frequencies in the tumor microenvironment (TME), compared to CB2R-deficient mice. In depth analysis of tumor-infiltrating B cells using single-cell RNA sequencing suggested a less differentiated phenotype in tumors from Cb2r−/− mice. Thus, in this study, we demonstrate for the first time a protective, B cell-mediated role of CB2R in melanoma. This gained insight might assist in the development of novel, CB2R-targeted cancer therapies.

31 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MKMirela Kremenovic
Mirela Kremenovic
NRNives Rombini
Nives Rombini
ACAlfred Chan
Alfred Chan
TGThomas Gruber
Thomas Gruber
LBLukas Bäriswyl
Lukas Bäriswyl
MSMirjam Schenk
Mirjam Schenk
Understanding the cellular interactions within the tumor microenvironment (TME) of melanoma paved the way for novel therapeutic modalities, such as T cell-targeted immune checkpoint inhibitors (ICI). However, only a limited fraction of patients benefits from such therapeutic modalities, highlighting the need for novel predictive and prognostic biomarkers. As myeloid cells orchestrate the tumor-specific immune response and influence the efficacy of ICI, assessing their activation state within the TME is of clinical relevance. Here, we characterized a myeloid activation (MA) signature, comprising the three genes Cxcl11, Gbp1, and Ido1, from gene expression data of human myeloid cells stimulated with poly(I:C) or cGAMP. This MA signature positively correlated to overall survival in melanoma. In addition, increased expression of the MA signature was observed in melanoma patients responding to ICI (anti-PD-1), as compared to non-responders. Furthermore, the MA signature was validated in the murine B16F10 melanoma model where it was induced and associated with decreased tumor growth upon intratumoral administration of poly(I:C) and cGAMP. Finally, we were able to visualize co-expression of the MA signature genes in myeloid cells of human melanoma tissues using RNAscope in situ hybridization. In conclusion, the MA signature indicates the activation state of myeloid cells and represents a prognostic biomarker for the overall survival in melanoma patients.